The boom of Viagra initially ignited significant expansion in the medicinal sector, generating a perception of substantial gains. However, placing capital in companies heavily reliant on blockbuster drugs like Sildenafil presents considerable challenges. Exclusive rights end has caused website off-brand rivalr… Read More

The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for revolutionary treatments and impressive returns is clear, the linked risks are also considerable. Many… Read More